BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: POLY , Columbia Care Inc. , Alleghany Corporation , Anaplan, Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.

POLY (NYSE - POLY)

Under the terms of the agreement, POLY will be acquired by HP Inc. ("HP") (NYSE - HPQ). POLY's shareholders will receive $40.00 in cash for each share of POLY common stock owned. The transaction is valued at approximately $3.3 billion. The investigation concerns whether the POLY Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether HP is paying too little for the Company. For example, the deal consideration is below the 52-week high for the Company's shares.

Additional information can be found at https://www.brodskysmith.com/cases/poly-nyse-poly/ .

Columbia Care Inc. (OTC - CCHWF)

Under the terms of the agreement, Columbia Care will be acquired by Cresco Labs ("Cresco Labs") (OTC - CRLBF). Shareholders of Columbia Care will receive 0.5579 of a subordinate voting share of Cresco Labs for each Columbia Care common share held, subject to adjustment, representing total consideration enterprise value of approximately $2 billion based on the closing price of Cresco Labs shares on the Canadian Securities Exchange as of March 22, 2022. The investigation concerns whether the Columbia Care Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Cresco Labs is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/columbia-care-inc-otc-cchwf/ .

Alleghany Corporation (NYSE - Y)

Under the terms of the agreement, Alleghany will be acquired by Berkshire Hathaway ("Berkshire") (NYSE - BRK.A; BRK.B). Alleghany's shareholders will receive $848.02 in cash for each share of Alleghany common stock owned. The transaction is valued at approximately $11.6 billion. The investigation concerns whether the Alleghany Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Berkshire is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/alleghany-corporation-nyse-y/ .

Anaplan, Inc. (NYSE - PLAN)

Under the terms of the agreement, Anaplan will be acquired by Thoma Bravo. Anaplan's shareholders will receive $66.00 in cash for each share of Anaplan common stock owned. The transaction is valued at approximately $10.7 billion. The investigation concerns whether the Anaplan Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Thoma Bravo is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/anaplan-inc-nyse-plan/ .

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

CL:CNX,CRLBF
The Conversation (0)
Gavel resting on cannabis leaves.

Cannabis Crossroads: Record US Demand Meets Federal Gridlock

The US cannabis industry is at a turning point. State-level legalization and retail growth continue to accelerate, but federal policy remains stalled, leaving businesses navigating both opportunity and uncertainty. Record consumer demand is driving sales, yet outdated regulations, restrictive... Keep Reading...
Cannabis leaf.

10 Biggest Cannabis Stocks in the US and Canada in 2025

After initial optimism for rescheduling in the US, the cannabis market has faced challenges in 2025. Despite signs of support from US President Donald Trump and members of his administration, regulatory uncertainty persists in the US. Companies are shifting focus to match changes in consumer... Keep Reading...
Field of cannabis plants under bright sunlight.

Cannabis Market Update: H1 2025 in Review

The first half of 2025 played out differently than many cannabis market participants expected. Heading into the year, there was optimism that rescheduling in the US would reduce or eliminate challenges, but the industry continued to grapple with persistent federal regulatory uncertainty,... Keep Reading...
Closeup of lush green cannabis leaves.

Thailand Reverses Course on Cannabis, Moves to Recriminalize Amid Political Fallout

Thailand’s groundbreaking experiment with cannabis decriminalization is rapidly unraveling, with the government formally moving to reclassify the plant as a narcotic and ban recreational sales.The decision has sent shockwaves through an industry once projected to be worth over US$1 billion.The... Keep Reading...
Cannabis leaf over map of Australia.

A State-by-State Guide to Cannabis in Australia

Australia federally legalised medicinal cannabis in 2016, and Australia's cannabis market has seen major growth since then.Medical cannabis approvals were up by 120 percent in the first half of 2023 compared to the same period in 2022. Statista forecasts that Australian cannabis revenue will... Keep Reading...
Cannabis leaf on road marked with "2025," with sunlight in the background.

New Cannabis Consumption Trends, Regulatory Shifts Seen Driving Market in 2025

Understanding trends in the cannabis industry is paramount for investors eyeing a market with steady growth potential, but the landscape is complex as products and regulations continue to evolve. Consumption habits are changing as edibles, vaping and THC beverages gain traction, especially among... Keep Reading...

Latest Press Releases

Related News